Drury, Ruth E. http://orcid.org/0000-0003-3581-543X
Camara, Susana
Chelysheva, Irina http://orcid.org/0000-0001-7802-7025
Bibi, Sagida
Sanders, Katherine
Felle, Salle http://orcid.org/0000-0001-7855-4482
Emary, Katherine
Phillips, Daniel http://orcid.org/0000-0003-0686-5091
Voysey, Merryn http://orcid.org/0000-0001-6324-6559
Ferreira, Daniela M. http://orcid.org/0000-0002-0594-0902
Klenerman, Paul
Gilbert, Sarah C. http://orcid.org/0000-0002-6823-9750
Lambe, Teresa http://orcid.org/0000-0001-7711-897X
Pollard, Andrew J. http://orcid.org/0000-0001-7361-719X
O’Connor, Daniel http://orcid.org/0000-0002-6902-9886
Funding for this research was provided by:
DH | National Institute for Health Research
Article History
Received: 18 June 2023
Accepted: 2 April 2024
First Online: 22 April 2024
Competing interests
: P.K. has received consultancy fees from AstraZeneca. S.C.G. is named as an inventor on the patent covering ChAdOx1 use as a vaccine vector and holds stock in Vaccitech. T.L. reports consulting fees from Vaccitech on an unrelated project, an honorarium from Seqirus, work-related investments, and is named as an inventor on a patent application for a vaccine against SARS-CoV-2. A.J.P. was a member of WHO’s Strategic Advisory Group of Experts on Immunization until January, 2022 and remains chair of the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation (JCVI) but does not participate in the JCVI COVID-19 committee; and reports providing advice to Shionogi on COVID-19, and funding from the NIHR, AstraZeneca, the Bill & Melinda Gates Foundation, Wellcome, the Medical Research Council, and the Coalition for Epidemic Preparedness Innovations. Oxford University has entered into a partnership with AstraZeneca for the development of COVID-19 vaccines.